Trial
NCT03565991
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Locally Advanced or Metastatic Solid Tumors
Intervention
Avelumab
Why stopped
The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-25